Introduction: Adenocarcinoma of the small bowel is a rare neoplasm presented usually in elder patients as a single tumor. Its presentation as multiple tumors and in young patients is exceptional and there aren't any guidelines to orient its therapy. Presentation of case: We present the rare case of a sixteen-year-old woman that presents to the emergency department with an intussusception due to a small bowel tumor. The resected specimen showed multiple adenocarcinomas. A complete endoscopic and PET-CT study showed other 5 lesions from the duodenum to the ileum that were resected. Genetic counseling showed no pathogenic changes. The final staging was T2N0M0 and only surveillance was indicated. The patient is now 3 years without any recurrence. Discussion: Multiple adenocarcinomas of the small bowel are a very infrequent presentation of the disease. Most common risk factors include Crohn disease and adenomas. Its presentation is usually vague with a delay in its diagnosis. The treatment remains mainly surgical with limited use of adjuvant therapy. The most important prognostic factor is lymph node involvement with 5-year survival that can range from 3%-60% depending on the stage. Conclusion: This case represents an exceptional presentation of a very rare pathology with few cases described in the literature. There isn't one single best study to stage the patient and surgery is still the standard of treatment while adjuvant therapies studies are being conducted. The young age and lack of predisposing factors or mutations leaves an open field for investigation. Highlights:
Despite the rapid advancements in genomics and the enactment of a new cancer law in Chile, the implementation of cancer genetic counseling continues to face significant challenges because of limited resources and infrastructure. We conducted a survey targeting health care providers who offer genetic counseling to patients with cancer and possess training in genetics and counseling. Additionally, we distributed a separate survey to high-risk patients associated with an advocacy group to gather insights on their perceptions of and experiences with cancer genetic counseling. Among the surveyed providers, 21% were nonmedical professionals who developed their skills through postgraduate continuing education programs. Germline testing was not performed in 47% of cases. Among the participants, 37% considered genetic counseling important for understanding the cause of their cancer, 25% valued knowing their risk of developing future tumors, and 33% believed it would benefit their current cancer treatment. Just over half of the patients (54%) had access to genetic counseling. Among those that received genetic counseling, 85% found it beneficial. In Chile, barriers to genetic counseling persist, particularly in rural areas and because of a shortage of trained professionals. Public policies recognizing genetic counseling’s importance are crucial, along with expanding training and infrastructure. Understanding patient perceptions and increasing the number of trained genetic counseling into cancer care, educating clinicians, and advocating for increased access are key steps for enhancing cancer treatment effectiveness in Chile.
El uso clínico de estudios genético-moleculares ha aumentado significativamente y existe acuerdo sobre la necesidad de informes claros, estructurados y clínicamente interpretables. Este documento representa un consenso intersocietario que establece recomendaciones sobre el diseño y reporte de estudios genético-moleculares en el contexto clínico. Su elaboración consideró la revisión de guías internacionales vigentes, así como su adaptación a la normativa y práctica nacional. El consenso fue desarrollado entre junio y diciembre de 2025 mediante un trabajo colaborativo entre la Rama de Genética de la Sociedad Chilena de Pediatría (SOCHIPE), la Sociedad de Genética de Chile (SOCHIGEN), la Sociedad Chilena de Asesoramiento Genético en Oncología (SOCHIAGO), la Sociedad Médica de Laboratorio Clínico (SMLC) y la Sociedad Chilena de Anatomía Patológica (SCHAP), con la colaboración técnica de representantes del Instituto de Salud Pública (ISP). Se realizaron reuniones periódicas y revisión iterativa de los contenidos. Se definieron los elementos esenciales que deben incluir los informes de estudios genéticos, tales como información administrativa y clínica, metodología, limitaciones, reporte de variantes, interpretación de resultados e implicancias clínicas. Asimismo, la recomendación de realización de asesoramiento genético y del proceso de consentimiento informado previo a la toma de exámenes genéticos. El objetivo de este documento es servir como referencia para laboratorios y profesionales de la salud, promoviendo la elaboración de informes claros, estructurados y clínicamente útiles. Se espera que su implementación contribuya a mejorar la calidad, homogeneidad e interpretación de los estudios genéticos, favoreciendo la toma de decisiones clínicas y la equidad en el acceso a diagnóstico.